Microbiome signature of diabetes detectable before diagnosis

 Clinical takeaway: Standard risk factors and glycemic testing still govern diabetes screening; microbiome analysis may eventually add risk information on top of age, BMI, and family history. 

By the time a fasting glucose or A1C climbs high enough to act on, insulin resistance has usually been building for years. The clinician has little to measure ahead of that inflection. The gut microbiome has looked like a candidate for that early window. 

Studies kept finding strong links between type 2 diabetes (T2D) and the bacterial makeup of the gut, but they often disagree on which species matter. A recent metagenomic analysis went after both questions at once, pairing stool sequencing with glucose measures in a population large enough to settle the species list and healthy enough to test how early the changes appear. 

Most of the microbiome signature of T2D was present in people who didn't yet have it. Of 789 species linked to T2D, 587 were also associated with prediabetes in adults taking no glucose-lowering medication. And 523 tracked with family history of diabetes in adults whose glucose was normal. The signature ran in both directions, with 168 species more abundant in T2D and 621 depleted. Medication didn't account for the pattern. Associations in medicated and unmedicated T2D correlated strongly, though they ran larger among the medicated. 

The signature reached adults no glucose test would flag. Among 135,093 normoglycemic adults, the species tied to higher post-meal glucose were largely the species tied to T2D. Across the full cohort, microbial differences grew more pronounced as insulin resistance increased. Enterocloster bolteae, a spore-former previously linked to poorer cardiovascular and metabolic health, ran more abundant in T2D. Romboutsia timonensis ran depleted. Part of the signature has never been isolated or cultivated in a lab. 

The findings come from stool metagenomics on 229,025 UK and US adults enrolled in the nutrition program of Zoe, a UK personalized nutrition company. Several authors are Zoe co-founders, employees, or consultants. Of the cohort, 3,687 had T2D and 14,022 had prediabetes. Species associations came from linear regression adjusted for age, sex, and BMI, pooled across seven sub-cohorts. Post-meal glucose in the normoglycemic subset came from continuous glucose monitors worn after standardized meals. 

The paper is under consideration at a medical journal, and the species list gives the field its sharpest target yet for the work that has to come next. The authors are explicit that microbiome analysis is not a candidate replacement for glycemic testing. 

"We know that lifestyle changes, like diet and physical activity, can prevent or delay the onset of T2D," said Gabriel Baldanzi, PhD, the study's first author and a postdoctoral researcher in the Laboratory of Computational Metagenomics at the University of Trento in Italy. "But people often struggle to notice these changes are working, beyond perhaps losing some weight. If we can detect early shifts in the gut microbiome and show someone they are on the right track, that could be a powerful source of motivation to keep going." 

Source: Baldanzi G, et al. (2026 Sep 28) 62nd EASD Annual Meeting, abstract 291. Human gut microbiome species linked to type 2 diabetes, insulin resistance, and glucose metabolism in >200,000 individuals